{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:00:17Z","timestamp":1785866417600,"version":"3.56.0"},"reference-count":125,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Financial support from the National Key Research and Development Program of China","award":["2022YFC3502200"],"award-info":[{"award-number":["2022YFC3502200"]}]},{"name":"the Fund for Scientific Research Platforms of South-Central Minzu University","award":["PTZ24024"],"award-info":[{"award-number":["PTZ24024"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81973208"],"award-info":[{"award-number":["No.81973208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["PGZQ11009"],"award-info":[{"award-number":["PGZQ11009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2706109","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:56:32Z","timestamp":1785862592000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Recent progress in small molecules targeting the acidic tumor microenvironment"],"prefix":"10.1080","volume":"41","author":[{"given":"Yinuo","family":"Fu","sequence":"first","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Song","sequence":"additional","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Guo","sequence":"additional","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowei","family":"Tang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhong","family":"Yang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, South-Central Minzu University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"12","key":"e_1_3_4_2_1","doi-asserted-by":"crossref","first-page":"e70496","DOI":"10.1002\/mco2.70496","article-title":"Dynamic evolution of the tumor immune microenvironment in malignant tumors and emerging therapeutic paradigms","volume":"6","author":"Sun Y","year":"2025","unstructured":"Sun Y, Shao C, Duan H, Wang Z, Xu S, Wang C, Xiu J, Liu J, Wang X, Yao X, et al. Dynamic evolution of the tumor immune microenvironment in malignant tumors and emerging therapeutic paradigms. MedComm (2020). 2025;6(12):e70496.","journal-title":"MedComm (2020)"},{"key":"e_1_3_4_3_1","doi-asserted-by":"crossref","first-page":"1225948","DOI":"10.3389\/fimmu.2023.1225948","article-title":"Unveiling tumor immune evasion mechanisms: abnormal expression of transporters on immune cells in the tumor microenvironment","volume":"14","author":"Chen L","year":"2023","unstructured":"Chen L, Wang Y, Hu Q, Liu Y, Qi X, Tang Z, Hu H, Lin N, Zeng S, Yu L, et al. Unveiling tumor immune evasion mechanisms: abnormal expression of transporters on immune cells in the tumor microenvironment. Front Immunol. 2023;14:1225948.","journal-title":"Front Immunol"},{"issue":"9","key":"e_1_3_4_4_1","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/cancers16091727","article-title":"The tumor stroma of squamous cell carcinoma: a complex environment that fuels cancer progression","volume":"16","author":"Buruian\u0103 A","year":"2024","unstructured":"Buruian\u0103 A, Gheban BA, Gheban-Ro\u0219ca IA, Georgiu C, Cri\u0219an D, Cri\u0219an M. The tumor stroma of squamous cell carcinoma: a complex environment that fuels cancer progression. Cancers (Basel). 2024;16(9):1727.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"e_1_3_4_5_1","doi-asserted-by":"crossref","first-page":"e3003276","DOI":"10.1371\/journal.pbio.3003276","article-title":"TiME for a change: the tumor microenvironment as the missing piece in cancer therapeutics","volume":"23","author":"Mo J","year":"2025","unstructured":"Mo J, Zhang H, Swarbrick A. TiME for a change: the tumor microenvironment as the missing piece in cancer therapeutics. PLoS Biol. 2025;23(7):e3003276.","journal-title":"PLoS Biol"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-L\u00f3pez KG","year":"2019","unstructured":"de la Cruz-L\u00f3pez KG, Castro-Mu\u00f1oz LJ, Reyes-Hern\u00e1ndez DO, Garc\u00eda-Carranc\u00e1 A, Manzo-Merino J. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 2019;9:1143.","journal-title":"Front Oncol"},{"key":"e_1_3_4_7_1","doi-asserted-by":"crossref","first-page":"116170","DOI":"10.1016\/j.ejmech.2024.116170","article-title":"pH regulators and their inhibitors in tumor microenvironment","volume":"267","author":"Liao S","year":"2024","unstructured":"Liao S, Wu G, Xie Z, Lei X, Yang X, Huang S, Deng X, Wang Z, Tang G. pH regulators and their inhibitors in tumor microenvironment. Eur J Med Chem. 2024;267:116170.","journal-title":"Eur J Med Chem"},{"issue":"24","key":"e_1_3_4_8_1","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.3390\/cancers14246028","article-title":"Revisiting the Warburg effect with focus on lactate","volume":"14","author":"Kocianova E","year":"2022","unstructured":"Kocianova E, Piatrikova V, Golias T. Revisiting the Warburg effect with focus on lactate. Cancers (Basel). 2022;14(24):6028.","journal-title":"Cancers (Basel)"},{"key":"e_1_3_4_9_1","doi-asserted-by":"crossref","first-page":"105051","DOI":"10.1016\/j.critrevonc.2025.105051","article-title":"The pH perspective of cancer: from Warburg\u2019s misconception to therapeutic targeting of pH regulating proteins","volume":"217","author":"Chen C","year":"2026","unstructured":"Chen C, Wang X, Yang T, Yuan X, Liang N, Yang Y, Yang X, Pang Y, Zhao Y, Li C, et al. The pH perspective of cancer: from Warburg\u2019s misconception to therapeutic targeting of pH regulating proteins. Crit Rev Oncol Hematol. 2026;217:105051.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"e_1_3_4_10_1","doi-asserted-by":"crossref","first-page":"189120","DOI":"10.1016\/j.bbcan.2024.189120","article-title":"Carbonic anhydrase IX: an atypical target for innovative therapies in cancer","volume":"1879","author":"Ronca R","year":"2024","unstructured":"Ronca R, Supuran CT. Carbonic anhydrase IX: an atypical target for innovative therapies in cancer. Biochim Biophys Acta Rev Cancer. 2024;1879(4):189120.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"e_1_3_4_11_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01900-0","article-title":"Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors","volume":"22","author":"Knopf P","year":"2023","unstructured":"Knopf P, Stowbur D, Hoffmann SHL, Hermann N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D, Krishnamachary B, et al. Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol Cancer. 2023;22(1):207.","journal-title":"Mol Cancer"},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","first-page":"621757","DOI":"10.3389\/fimmu.2020.621757","article-title":"Warburg effect is a cancer immune evasion mechanism against macrophage immunosurveillance","volume":"11","author":"Chen J","year":"2020","unstructured":"Chen J, Cao X, Li B, Zhao Z, Chen S, Lai SWT, Muend SA, Nossa GK, Wang L, Guo W, et al. Warburg effect is a cancer immune evasion mechanism against macrophage immunosurveillance. Front Immunol. 2020;11:621757.","journal-title":"Front Immunol"},{"key":"e_1_3_4_13_1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jconrel.2022.08.031","article-title":"Oral administration of sodium bicarbonate can enhance the therapeutic outcome of Doxil\u00ae via neutralizing the acidic tumor microenvironment","volume":"350","author":"Ando H","year":"2022","unstructured":"Ando H, Ikeda A, Tagami M, Matsuo NCA, Shimizu T, Ishima Y, Eshima K, Ishida T. Oral administration of sodium bicarbonate can enhance the therapeutic outcome of Doxil\u00ae via neutralizing the acidic tumor microenvironment. J Control Release. 2022;350:414\u2013420.","journal-title":"J Control Release"},{"key":"e_1_3_4_14_1","doi-asserted-by":"crossref","first-page":"122607","DOI":"10.1016\/j.biomaterials.2024.122607","article-title":"Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors","volume":"309","author":"Shi T","year":"2024","unstructured":"Shi T, Sun M, Tuerhong S, Li M, Wang J, Wang Y, Zheng Q, Zou L, Lu C, Sun Z, et al. Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors. Biomaterials. 2024;309:122607.","journal-title":"Biomaterials"},{"issue":"10","key":"e_1_3_4_15_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri D","year":"2011","unstructured":"Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10(10):767\u2013777.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","first-page":"979154","DOI":"10.3389\/fonc.2022.979154","article-title":"Tumor acidity: from hallmark of cancer to target of treatment","volume":"12","author":"Bogdanov A","year":"2022","unstructured":"Bogdanov A, Bogdanov A, Chubenko V, Volkov N, Moiseenko F, Moiseyenko V. Tumor acidity: from hallmark of cancer to target of treatment. Front Oncol. 2022;12:979154.","journal-title":"Front Oncol"},{"issue":"11","key":"e_1_3_4_17_1","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.3390\/cancers12113244","article-title":"Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment","volume":"12","author":"P\u00e9rez-Tom\u00e1s R","year":"2020","unstructured":"P\u00e9rez-Tom\u00e1s R, P\u00e9rez-Guill\u00e9n I. Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment. Cancers (Basel). 2020;12(11):3244.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.3390\/ijms27073245","article-title":"Suppression of tumor aggression through metabolic reprogramming via oxamate targeting LDHA","volume":"27","author":"Stepanov YV","year":"2026","unstructured":"Stepanov YV, Solyanik GI, Yakshibaeva Y, Kolesnik D, Stepanova LI, Golovynska I. Suppression of tumor aggression through metabolic reprogramming via oxamate targeting LDHA. Int J Mol Sci. 2026;27(7):3245.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","first-page":"112686","DOI":"10.1016\/j.biopha.2022.112686","article-title":"Oxamate targeting aggressive cancers with special emphasis to brain tumors","volume":"147","author":"Altinoz MA","year":"2022","unstructured":"Altinoz MA, Ozpinar A. Oxamate targeting aggressive cancers with special emphasis to brain tumors. Biomed Pharmacother. 2022;147:112686.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"e_1_3_4_20_1","first-page":"311","volume":"7","author":"Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini, E, Buonfiglio R, Roberti M, Recanatin M.","unstructured":"Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini, E, Buonfiglio R, Roberti M, Recanatin M. Galloflavin (CAS 568\u201080\u20109): a novel inhibitor of lactate dehydrogenase. ChemMedChem. 2011; 7(2):311\u2013317.","journal-title":"2011;"},{"issue":"10","key":"e_1_3_4_21_1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1021\/acsmedchemlett.6b00190","article-title":"Cell active hydroxylactam inhibitors of human lactate dehydrogenase with oral bioavailability in mice","volume":"7","author":"Purkey HE","year":"2016","unstructured":"Purkey HE, Robarge K, Chen J, Chen Z, Corson LB, Ding CZ, DiPasquale AG, Dragovich PS, Eigenbrot C, Evangelista M, et al. Cell active hydroxylactam inhibitors of human lactate dehydrogenase with oral bioavailability in mice. ACS Med Chem Lett. 2016;7(10):896\u2013901.","journal-title":"ACS Med Chem Lett"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","first-page":"116598","DOI":"10.1016\/j.ejmech.2024.116598","article-title":"Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer","volume":"275","author":"Sharma H","year":"2024","unstructured":"Sharma H, Mondal S, Urquiza U, Esparza C, Bartlett S, Santa-Pinter L, Hill H, White M, Sharma P, Luckett-Chastain L, et al. Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur J Med Chem. 2024;275:116598.","journal-title":"Eur J Med Chem"},{"issue":"20","key":"e_1_3_4_23_1","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1158\/1078-0432.CCR-12-0859","article-title":"Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells","volume":"18","author":"Tamada M","year":"2012","unstructured":"Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res. 2012;18(20):5554\u20135561.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"e_1_3_4_24_1","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.7150\/jca.58494","article-title":"Shikonin inhibits tumor growth of ESCC by suppressing PKM2 mediated aerobic glycolysis and STAT3 phosphorylation","volume":"12","author":"Zhang Q","year":"2021","unstructured":"Zhang Q, Liu Q, Zheng S, Liu T, Yang L, Han X, Lu X. Shikonin inhibits tumor growth of ESCC by suppressing PKM2 mediated aerobic glycolysis and STAT3 phosphorylation. J Cancer. 2021;12(16):4830\u20134840.","journal-title":"J Cancer"},{"key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2020.11.018","article-title":"Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics","volume":"503","author":"Zhu S","year":"2021","unstructured":"Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X, Peng C. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2021;503:240\u2013248.","journal-title":"Cancer Lett"},{"key":"e_1_3_4_26_1","doi-asserted-by":"crossref","first-page":"1649488","DOI":"10.3389\/fimmu.2025.1649488","article-title":"Targeting PKM2 in cancer therapeutics: mechanistic advances and translational opportunities","volume":"16","author":"Liu L","year":"2025","unstructured":"Liu L, Wang J, Liang L, Chen C, Xie M, Tang W. Targeting PKM2 in cancer therapeutics: mechanistic advances and translational opportunities. Front Immunol. 2025;16:1649488.","journal-title":"Front Immunol"},{"issue":"5","key":"e_1_3_4_27_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/fon.09.44","article-title":"Targeting glucose metabolism with 2-deoxy-d-glucose for improving cancer therapy","volume":"5","author":"Dwarakanath B","year":"2009","unstructured":"Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-d-glucose for improving cancer therapy. Future Oncol. 2009;5(5):581\u2013585.","journal-title":"Future Oncol"},{"issue":"2","key":"e_1_3_4_28_1","first-page":"151","article-title":"Mechanism of antineoplastic activity of lonidamine","volume":"1866","author":"Nath K","year":"2016","unstructured":"Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee S-C, Roman J, Zhou R, Leeper DB, Halestrap AP, et al. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866(2):151\u2013162.","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"e_1_3_4_29_1","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.3390\/cancers12113332","article-title":"The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment","volume":"12","author":"Huang Y","year":"2020","unstructured":"Huang Y, Sun G, Sun X, Li F, Zhao L, Zhong R, Peng Y. The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment. Cancers (Basel). 2020;12(11):3332.","journal-title":"Cancers (Basel)"},{"key":"e_1_3_4_30_1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/CMAR.S421771","article-title":"Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment","volume":"15","author":"Liu T","year":"2023","unstructured":"Liu T, Han S, Yao Y, Zhang G. Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment. Cancer Manag Res. 2023;15:957\u2013975.","journal-title":"Cancer Manag Res"},{"key":"e_1_3_4_31_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","article-title":"Monocarboxylate transporters in cancer","volume":"33","author":"Payen VL","year":"2020","unstructured":"Payen VL, Mina E, Van H\u00e9e VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48\u201366.","journal-title":"Mol Metab"},{"issue":"19","key":"e_1_3_4_32_1","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bph.70110","article-title":"Role of monocarboxylate transporters in cancer immunology and their therapeutic potential","volume":"182","author":"Faghihkhorasani F","year":"2025","unstructured":"Faghihkhorasani F, Moosavi M, Rasool Riyadh Abdulwahid A-H, Kavei M, Karimi S, Seyed Karimi M, Vezvaei P, Manafi Varkiani M, Aref AR, Ebrahimi N, et al. Role of monocarboxylate transporters in cancer immunology and their therapeutic potential. Br J Pharmacol. 2025;182(19):4421\u20134457.","journal-title":"Br J Pharmacol"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","first-page":"112393","DOI":"10.1016\/j.ejmech.2020.112393","article-title":"Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: a review with structure\u2013activity relationship insights","volume":"199","author":"Puri S","year":"2020","unstructured":"Puri S, Juvale K. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: a review with structure\u2013activity relationship insights. Eur J Med Chem. 2020;199:112393.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_34_1","doi-asserted-by":"crossref","first-page":"1069555","DOI":"10.3389\/fcell.2022.1069555","article-title":"Proton-coupled monocarboxylate transporters in cancer: from metabolic crosstalk, immunosuppression and anti-apoptosis to clinical applications","volume":"10","author":"Duan Q","year":"2022","unstructured":"Duan Q, Zhang S, Wang Y, Lu D, Sun Y, Wu Y. Proton-coupled monocarboxylate transporters in cancer: from metabolic crosstalk, immunosuppression and anti-apoptosis to clinical applications. Front Cell Dev Biol. 2022;10:1069555.","journal-title":"Front Cell Dev Biol"},{"issue":"13","key":"e_1_3_4_35_1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2174\/1389557519666190311154425","article-title":"Pharmacological aspects and potential use of phloretin: a systemic review","volume":"19","author":"Mariadoss AVA","year":"2019","unstructured":"Mariadoss AVA, Vinyagam R, Rajamanickam V, Sankaran V, Venkatesan S, David E. Pharmacological aspects and potential use of phloretin: a systemic review. MRMC. 2019;19(13):1060\u20131067.","journal-title":"MRMC"},{"issue":"5","key":"e_1_3_4_36_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1021\/acsmedchemlett.5b00049","article-title":"Monocarboxylate transporter 1 inhibitors as potential anticancer agents","volume":"6","author":"Gurrapu S","year":"2015","unstructured":"Gurrapu S, Jonnalagadda SK, Alam MA, Nelson GL, Sneve MG, Drewes LR, Mereddy VR. Monocarboxylate transporter 1 inhibitors as potential anticancer agents. ACS Med Chem Lett. 2015;6(5):558\u2013561.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"18266","DOI":"10.1038\/s41598-019-54709-7","article-title":"Development of novel silyl cyanocinnamic acid derivatives as metabolic plasticity inhibitors for cancer treatment","volume":"9","author":"Nelson GL","year":"2019","unstructured":"Nelson GL, Ronayne CT, Solano LN, Jonnalagadda SK, Jonnalagadda S, Rumbley J, Holy J, Rose-Hellekant T, Drewes LR, Mereddy VR, et al. Development of novel silyl cyanocinnamic acid derivatives as metabolic plasticity inhibitors for cancer treatment. Sci Rep. 2019;9(1):18266.","journal-title":"Sci Rep"},{"issue":"8","key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer","volume":"29","author":"Halford S","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, et al. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. 2023;29(8):1429\u20131439.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"e_1_3_4_39_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/BJ20091515","article-title":"AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7\u201310","volume":"425","author":"Ovens MJ","year":"2010","unstructured":"Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7\u201310. Biochem J. 2010;425(3):523\u2013530.","journal-title":"Biochem J"},{"issue":"11","key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-17-1253","article-title":"Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance","volume":"17","author":"Quanz M","year":"2018","unstructured":"Quanz M, Bender E, Kopitz C, Gr\u00fcnewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, et al. Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance. Mol Cancer Ther. 2018;17(11):2285\u20132296.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"e_1_3_4_41_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acs.jmedchem.2c01612","article-title":"Indole derivatives as new structural class of potent and antiproliferative inhibitors of monocarboxylate transporter 1 (MCT1; SLC16A1)","volume":"66","author":"Puri S","year":"2023","unstructured":"Puri S, Stefan K, Khan SL, Pahnke J, Stefan SM, Juvale K. Indole derivatives as new structural class of potent and antiproliferative inhibitors of monocarboxylate transporter 1 (MCT1; SLC16A1). J Med Chem. 2023;66(1):657\u2013676.","journal-title":"J Med Chem"},{"issue":"8","key":"e_1_3_4_42_1","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1038\/s41401-025-01517-7","article-title":"Transport mechanism and drug discovery of human monocarboxylate transporter 1","volume":"46","author":"Shi S","year":"2025","unstructured":"Shi S, Li J-C, Zhou X-Y, Li Z-L, Wang Y-X, Xu B-H, Ye S. Transport mechanism and drug discovery of human monocarboxylate transporter 1. Acta Pharmacol Sin. 2025;46(8):2323\u20132333.","journal-title":"Acta Pharmacol Sin"},{"issue":"14","key":"e_1_3_4_43_1","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1074\/jbc.M511397200","article-title":"The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1\u03b1-dependent mechanism","volume":"281","author":"Ullah MS","year":"2006","unstructured":"Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1\u03b1-dependent mechanism. J Biol Chem. 2006;281(14):9030\u20139037.","journal-title":"J Biol Chem"},{"issue":"11","key":"e_1_3_4_44_1","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1016\/j.celrep.2018.11.043","article-title":"Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells","volume":"25","author":"Benjamin D","year":"2018","unstructured":"Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY, Maira S-M, Moroni C, Lane HA, Hall MN, et al. Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells. Cell Rep. 2018;25(11):3047\u20133058.e4. e4.","journal-title":"Cell Rep"},{"issue":"1","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/acs.jmedchem.2c01342","article-title":"Discovery of clinical candidate AZD0095, a selective inhibitor of monocarboxylate transporter 4 (MCT4) for oncology","volume":"66","author":"Goldberg FW","year":"2023","unstructured":"Goldberg FW, Kettle JG, Lamont GM, Buttar D, Ting AKT, McGuire TM, Cook CR, Beattie D, Morentin Gutierrez P, Kavanagh SL, et al. Discovery of clinical candidate AZD0095, a selective inhibitor of monocarboxylate transporter 4 (MCT4) for oncology. J Med Chem. 2023;66(1):384\u2013397.","journal-title":"J Med Chem"},{"key":"e_1_3_4_46_1","doi-asserted-by":"crossref","first-page":"154618","DOI":"10.1016\/j.phymed.2022.154618","article-title":"Formosanin C inhibits non-small-cell lung cancer progression by blocking MCT4\/CD147-mediated lactate export","volume":"109","author":"Li J","year":"2023","unstructured":"Li J, Wu Z, Chen G, Wang X, Zhu X, Zhang Y, Zhang R, Wu W, Zhu Y, Ma L, et al. Formosanin C inhibits non-small-cell lung cancer progression by blocking MCT4\/CD147-mediated lactate export. Phytomedicine. 2023;109:154618.","journal-title":"Phytomedicine"},{"issue":"24","key":"e_1_3_4_47_1","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.18632\/oncotarget.26760","article-title":"Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors","volume":"10","author":"Jonnalagadda S","year":"2019","unstructured":"Jonnalagadda S, Jonnalagadda SK, Ronayne CT, Nelson GL, Solano LN, Rumbley J, Holy J, Mereddy VR, Drewes LR. Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors. Oncotarget. 2019;10(24):2355\u20132368.","journal-title":"Oncotarget"},{"issue":"7","key":"e_1_3_4_48_1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1042\/BJ20151120","article-title":"The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters","volume":"473","author":"Nancolas B","year":"2016","unstructured":"Nancolas B, Guo L, Zhou R, Nath K, Nelson DS, Leeper DB, Blair IA, Glickson JD, Halestrap AP. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016;473(7):929\u2013936.","journal-title":"Biochem J"},{"issue":"29","key":"e_1_3_4_49_1","doi-asserted-by":"crossref","first-page":"27213","DOI":"10.1074\/jbc.M411950200","article-title":"Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4","volume":"280","author":"Wilson MC","year":"2005","unstructured":"Wilson MC, Meredith D, Fox JEM, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4. J Biol Chem. 2005;280(29):27213\u201327221.","journal-title":"J Biol Chem"},{"issue":"9","key":"e_1_3_4_50_1","doi-asserted-by":"crossref","first-page":"109202","DOI":"10.1016\/j.celrep.2021.109202","article-title":"Therapy-induced DNA methylation inactivates MCT1 and renders tumor cells vulnerable to MCT4 inhibition","volume":"35","author":"Vander Linden C","year":"2021","unstructured":"Vander Linden C, Corbet C, Bastien E, Martherus R, Guilbaud C, Petit L, Wauthier L, Loriot A, De Smet C, Feron O, et al. Therapy-induced DNA methylation inactivates MCT1 and renders tumor cells vulnerable to MCT4 inhibition. Cell Rep. 2021;35(9):109202.","journal-title":"Cell Rep"},{"issue":"14","key":"e_1_3_4_51_1","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.3390\/cancers13143635","article-title":"PXR modulates the prostate cancer cell response to afatinib by regulating the expression of the monocarboxylate transporter SLC16A1","volume":"13","author":"Matheux A","year":"2021","unstructured":"Matheux A, Gassiot M, Fromont G, Leenhardt F, Boulahtouf A, Fabbrizio E, Marchive C, Garcin A, Agherbi H, Comb\u00e8s E, et al. PXR modulates the prostate cancer cell response to afatinib by regulating the expression of the monocarboxylate transporter SLC16A1. Cancers (Basel). 2021;13(14):3635.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"e_1_3_4_52_1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrc1713","article-title":"The role of disturbed pH dynamics and the Na+\/H\u2009+\u2009exchanger in metastasis","volume":"5","author":"Cardone RA","year":"2005","unstructured":"Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+\/H\u2009+\u2009exchanger in metastasis. Nat Rev Cancer. 2005;5(10):786\u2013795.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_53_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2016.12.001","article-title":"Roles of pH and the Na +\/H\u2009+\u2009exchanger NHE1 in cancer: from cell biology and animal models to an emerging translational perspective?","volume":"43","author":"Stock C","year":"2017","unstructured":"Stock C, Pedersen SF. Roles of pH and the Na +\/H\u2009+\u2009exchanger NHE1 in cancer: from cell biology and animal models to an emerging translational perspective? Semin Cancer Biol. 2017;43:5\u201316.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"e_1_3_4_54_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/0008-5472.CAN-12-4031","article-title":"Regulation of the Na+\/H\u2009+\u2009exchanger (NHE1)in breast cancer metastasis","volume":"73","author":"Amith SR","year":"2013","unstructured":"Amith SR, Fliegel L. Regulation of the Na+\/H\u2009+\u2009exchanger (NHE1)in breast cancer metastasis. Cancer Res. 2013;73(4):1259\u20131264.","journal-title":"Cancer Res"},{"key":"e_1_3_4_55_1","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.neo.2022.100862","article-title":"Targeting Na-H exchanger 1 overcomes nuclear factor kappa B-mediated tumor resistance to radiotherapy","volume":"35","author":"Son A","year":"2023","unstructured":"Son A, Kang S, Choi S, Shin S-W, Kim Y, Kim W, Choi C. Targeting Na-H exchanger 1 overcomes nuclear factor kappa B-mediated tumor resistance to radiotherapy. Neoplasia. 2023;35:100862.","journal-title":"Neoplasia"},{"issue":"6","key":"e_1_3_4_56_1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.3390\/ijms22062999","article-title":"Screening of 5-and 6-substituted amiloride libraries identifies dual-uPA\/NHE1 active and single target-selective inhibitors","volume":"22","author":"Buckley BJ","year":"2021","unstructured":"Buckley BJ, Kumar A, Aboelela A, Bujaroski RS, Li X, Majed H, Fliegel L, Ranson M, Kelso MJ. Screening of 5-and 6-substituted amiloride libraries identifies dual-uPA\/NHE1 active and single target-selective inhibitors. Int J Mol Sci. 2021;22(6):2999.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"e_1_3_4_57_1","first-page":"1","article-title":"Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo","volume":"19","author":"Chen Q","year":"2019","unstructured":"Chen Q, Liu Y, Lan ZX, Feng F, Yang H, Xu W. Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo. BMC Cancer. 2019;19(1):1\u201313.","journal-title":"BMC Cancer"},{"issue":"7","key":"e_1_3_4_58_1","doi-asserted-by":"crossref","first-page":"167450","DOI":"10.1016\/j.bbadis.2024.167450","article-title":"Na+\/H+-exchange inhibition by cariporide is compensated via Na+,HCO3\n                  \u2212-cotransport and has no net growth consequences for ErbB2-driven breast carcinomas","volume":"1870","author":"Aaen P","year":"2024","unstructured":"Aaen P, Kristensen KB, Antony A, Hansen SH, Cornett C, Pedersen SF, Boedtkjer E. Na+\/H+-exchange inhibition by cariporide is compensated via Na+,HCO3\u2212-cotransport and has no net growth consequences for ErbB2-driven breast carcinomas. Biochim Biophys Acta(BBA) Mol Basis Dis. 2024;1870(7):167450.","journal-title":"Biochim Biophys Acta(BBA) Mol Basis Dis"},{"issue":"6","key":"e_1_3_4_59_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0960-894X(01)00059-2","article-title":"Discovery of zoniporide: a potent and selective sodium\u2013hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility","volume":"11","author":"Guzman-Perez A","unstructured":"Guzman-Perez A, Wester RT, Allen MC, et al. Discovery of zoniporide: a potent and selective sodium\u2013hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg Med Chem Lett. 2001;11(6):803\u2013807.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"e_1_3_4_60_1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1476-5381.1993.tb13607.x","article-title":"Hoe 694, a new Na+\/H\u2009+\u2009exchange inhibitor and its effects in cardiac ischaemia","volume":"109","author":"Scholz W","year":"1993","unstructured":"Scholz W, Albus U, Lang HJ, Linz W, Martorana PA, Englert HC, Sch\u00f6lkens BA. Hoe 694, a new Na+\/H\u2009+\u2009exchange inhibitor and its effects in cardiac ischaemia. Br J Pharmacol. 1993;109(2):562\u2013568.","journal-title":"Br J Pharmacol"},{"issue":"13","key":"e_1_3_4_61_1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/jm960768n","article-title":"2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+\/H\u2009+\u2009antiporter inhibitors","volume":"40","author":"Baumgarth M","year":"1997","unstructured":"Baumgarth M, Beier N, Gericke R. (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+\/H\u2009+\u2009antiporter inhibitors. J Med Chem. 1997;40(13):2017\u20132034.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_4_62_1","doi-asserted-by":"crossref","first-page":"17573","DOI":"10.3390\/ijms140917573","article-title":"Prevention of carcinogenesis and development of gastric and colon cancers by 2-aminophenoxazine-3-one (Phx-3): direct and indirect anti-cancer activity of Phx-3","volume":"14","author":"Tomoda A","year":"2013","unstructured":"Tomoda A, Miyazawa K, Tabuchi T. Prevention of carcinogenesis and development of gastric and colon cancers by 2-aminophenoxazine-3-one (Phx-3): direct and indirect anti-cancer activity of Phx-3. Int J Mol Sci. 2013;14(9):17573\u201317583.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_63_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2016.08.010","article-title":"KR-33028, a potent inhibitor of the Na+\/H\u2009+\u2009exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells","volume":"118","author":"Amith SR","year":"2016","unstructured":"Amith SR, Wilkinson JM, Fliegel L. KR-33028, a potent inhibitor of the Na+\/H\u2009+\u2009exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells. Biochem Pharmacol. 2016;118:31\u201339.","journal-title":"Biochem Pharmacol"},{"issue":"20","key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm010100v","article-title":"Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1","volume":"44","author":"Ahmad S","year":"2001","unstructured":"Ahmad S, Doweyko LM, Dugar S, Grazier N, Ngu K, Wu SC, Yost KJ, Chen BC, Gougoutas JZ, DiMarco JD, et al. Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1. J Med Chem. 2001;44(20):3302\u20133310.","journal-title":"J Med Chem"},{"issue":"8","key":"e_1_3_4_65_1","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41388-019-1098-6","article-title":"CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells","volume":"39","author":"Ames S","year":"2020","unstructured":"Ames S, Andring JT, McKenna R, Becker HM. CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells. Oncogene. 2020;39(8):1710\u20131723.","journal-title":"Oncogene"},{"key":"e_1_3_4_66_1","doi-asserted-by":"crossref","first-page":"1444452","DOI":"10.3389\/fimmu.2024.1444452","article-title":"Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance","volume":"15","author":"Wu X","year":"2024","unstructured":"Wu X, Feng N, Wang C, Jiang H, Guo Z. Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance. Front Immunol. 2024;15:1444452.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_4_67_1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/1479-5876-11-282","article-title":"Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs: an integral molecular\/biochemical\/metabolic\/clinical approach after one hundred years of cancer research","volume":"11","author":"Harguindey S","year":"2013","unstructured":"Harguindey S, Arranz J, Polo Orozco J, Rauch C, Fais S, Cardone R, Reshkin SJ. Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs: an integral molecular\/biochemical\/metabolic\/clinical approach after one hundred years of cancer research. J Transl Med. 2013;11(1):282.","journal-title":"J Transl Med"},{"issue":"1","key":"e_1_3_4_68_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01998-9","article-title":"V-ATPase in cancer: mechanistic insights and therapeutic potentials","volume":"22","author":"Chen T","year":"2024","unstructured":"Chen T, Lin X, Lu S, Li B. V-ATPase in cancer: mechanistic insights and therapeutic potentials. Cell Commun Signal. 2024;22(1):613.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"e_1_3_4_69_1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2217\/14796694.1.6.779","article-title":"Tumor acidity, chemoresistance and proton pump inhibitors","volume":"1","author":"De Milito A","year":"2005","unstructured":"De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Fut Oncol. 2005;1(6):779\u2013786.","journal-title":"Fut Oncol"},{"issue":"22","key":"e_1_3_4_70_1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/jnci\/djh305","article-title":"Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs","volume":"96","author":"Luciani F","year":"2004","unstructured":"Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702\u20131713.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"e_1_3_4_71_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1042\/bj20021411","article-title":"Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells","volume":"370","author":"Ouar Z","year":"2003","unstructured":"Ouar Z, Bens M, Vignes C, Paulais M, Pringel C, Fleury J, Cluzeaud F, Lacave R, Vandewalle A. Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J. 2003;370(Pt 1):185\u2013193.","journal-title":"Biochem J"},{"issue":"17","key":"e_1_3_4_72_1","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.3390\/jcm12175546","article-title":"Vacuolar ATPase is a possible therapeutic target in acute myeloid leukemia: focus on patient heterogeneity and treatment toxicity","volume":"12","author":"Bartaula-Brevik S","year":"2023","unstructured":"Bartaula-Brevik S, Leitch C, Hernandez-Valladares M, Aaseb\u00f8 E, Berven FS, Selheim F, Brenner AK, Rye KP, Hagen M, Reikvam H, et al. Vacuolar ATPase is a possible therapeutic target in acute myeloid leukemia: focus on patient heterogeneity and treatment toxicity. J Clin Med. 2023;12(17):5546.","journal-title":"J Clin Med"},{"issue":"41","key":"e_1_3_4_73_1","doi-asserted-by":"crossref","first-page":"43508","DOI":"10.18632\/oncotarget.6180","article-title":"Anti-leukemic effects of the V-ATPase inhibitor archazolid A","volume":"6","author":"Zhang S","year":"2015","unstructured":"Zhang S, Schneider LS, Vick B, Grunert M, Jeremias I, Menche D, M\u00fcller R, Vollmar AM, Liebl J. Anti-leukemic effects of the V-ATPase inhibitor archazolid A. Oncotarget. 2015;6(41):43508\u201343528.","journal-title":"Oncotarget"},{"issue":"46","key":"e_1_3_4_74_1","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1074\/jbc.RA119.010243","article-title":"Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells","volume":"294","author":"Bartel K","year":"2019","unstructured":"Bartel K, M\u00fcller R, von Schwarzenberg K. Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells. J Biol Chem. 2019;294(46):17239\u201317248.","journal-title":"J Biol Chem"},{"key":"e_1_3_4_75_1","doi-asserted-by":"crossref","first-page":"101100","DOI":"10.1016\/j.drup.2024.101100","article-title":"Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration","volume":"76","author":"Ji N","year":"2024","unstructured":"Ji N, Li H, Zhang Y, Li Y, Wang P, Chen X, Liu Y-N, Wang J-Q, Yang Y, Chen Z-S, et al. Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration. Drug Resist Updat. 2024;76:101100.","journal-title":"Drug Resist Updat"},{"issue":"7","key":"e_1_3_4_76_1","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.7150\/ijbs.71041","article-title":"Toosendanin, a novel potent vacuolar-type H+-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy","volume":"18","author":"Dong Y","year":"2022","unstructured":"Dong Y, Zhu G, Wang S-F, Keon KA, Rubinstein JL, Zeng S-X, Zhang S, Chen Q-L, Fu J, Li M, et al. Toosendanin, a novel potent vacuolar-type H+-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy. Int J Biol Sci. 2022;18(7):2684\u20132702.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"e_1_3_4_77_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ijc.25009","article-title":"pH\u2010dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity","volume":"127","author":"De Milito A","year":"2010","unstructured":"De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, et al. pH\u2010dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127(1):207\u2013219.","journal-title":"Int J Cancer"},{"issue":"7","key":"e_1_3_4_78_1","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.7150\/ijbs.106843","article-title":"Integrated thermal proteome and thermal proximity co-aggregation profiling identifies ATP6V1C1 as a novel anti-cancer drug target","volume":"21","author":"Zhang S","year":"2025","unstructured":"Zhang S, Li F-M, Wang J, Dong Y, Luo J-F, Huang X-F, Li Y, Zhu G-Y, Qi S-Q, Shen H-M, et al. Integrated thermal proteome and thermal proximity co-aggregation profiling identifies ATP6V1C1 as a novel anti-cancer drug target. Int J Biol Sci. 2025;21(7):3197\u20133213.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"e_1_3_4_79_1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.chembiol.2020.06.011","article-title":"Pharmacological targeting of vacuolar H+-ATPase via subunit V1G combats multidrug-resistant cancer","volume":"27","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang L, Wei Y, Huang W, Li L, Wu A-A, Dastur A, Greninger P, Bray WM, Zhang C-S, et al. Pharmacological targeting of vacuolar H+-ATPase via subunit V1G combats multidrug-resistant cancer. Cell Chem Biol. 2020;27(11):1359\u20131370.e8.","journal-title":"Cell Chem Biol"},{"issue":"12","key":"e_1_3_4_80_1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41587-022-01386-z","article-title":"Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice","volume":"40","author":"Tolani B","year":"2022","unstructured":"Tolani B, Celli A, Yao Y, Tan YZ, Fetter R, Liem CR, de Smith AJ, Vasanthakumar T, Bisignano P, Cotton AD, et al. Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice. Nat Biotechnol. 2022;40(12):1834\u20131844.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"e_1_3_4_81_1","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1021\/acs.jmedchem.3c02399","article-title":"Discovery of novel isoquinoline analogues as dual tubulin polymerization\/V-ATPAse inhibitors with immunogenic cell death induction","volume":"67","author":"Leng J","year":"2024","unstructured":"Leng J, Zhao Y, Zhao S, Xie S, Sheng P, Zhu L, Zhang M, Chen T, Kong L, Yin Y, et al. Discovery of novel isoquinoline analogues as dual tubulin polymerization\/V-ATPAse inhibitors with immunogenic cell death induction. J Med Chem. 2024;67(4):3144\u20133166.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_4_82_1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/molecules22091559","article-title":"Identification of novel bisbenzimidazole derivatives as anticancer vacuolar(H+)-ATPase inhibitors","volume":"22","author":"Patil R","year":"2017","unstructured":"Patil R, Kulshrestha A, Tikoo A, Fleetwood S, Katara G, Kolli B, Seibel W, Gilman-Sachs A, Patil SA, Beaman KD, et al. Identification of novel bisbenzimidazole derivatives as anticancer vacuolar(H+)-ATPase inhibitors. Molecules. 2017;22(9):1559.","journal-title":"Molecules"},{"issue":"1","key":"e_1_3_4_83_1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1749-6632.2009.04705.x","article-title":"Biological effects of a new vacuolar\u2010H,+\u2010ATPase inhibitor in colon carcinoma cell lines","volume":"1171","author":"Supino R","year":"2009","unstructured":"Supino R, Scovassi AI, Croce AC, Bo LD, Favini E, Corbelli A, Farina C, Misiano P, Zunino F. Biological effects of a new vacuolar\u2010H,+\u2010ATPase inhibitor in colon carcinoma cell lines. Ann N Y Acad Sci. 2009;1171(1):606\u2013616.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"e_1_3_4_84_1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1248\/bpb.b20-00825","article-title":"Neutralization of acidic tumor microenvironment (TME) with daily oral dosing of sodium potassium citrate (K\/Na citrate) increases therapeutic effect of anti-cancer agent in pancreatic cancer xenograft mice model","volume":"44","author":"Ando H","year":"2021","unstructured":"Ando H, Eshima K, Ishida T. Neutralization of acidic tumor microenvironment (TME) with daily oral dosing of sodium potassium citrate (K\/Na citrate) increases therapeutic effect of anti-cancer agent in pancreatic cancer xenograft mice model. Biol Pharm Bull. 2021;44(2):266\u2013270.","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"e_1_3_4_85_1","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/0008-5472.CAN-07-5575","article-title":"Bicarbonate increases tumor pH and inhibits spontaneous metastases","volume":"69","author":"Robey IF","year":"2009","unstructured":"Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009;69(6):2260\u20132268.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_4_86_1","article-title":"The dysadherin\/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression","volume":"11","author":"Lee C-J","year":"2026","unstructured":"Lee C-J, Yun H-J, Jang T-Y, Jeon S-E, Cho Y-H, Lim D-Y, Han E-J, Kong S-Y, Nam J-S. The dysadherin\/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. Sig Transduct Target Ther. 2026;11(1):19.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"e_1_3_4_87_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13058-023-01644-1","article-title":"Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2\/HER2-enriched breast cancer","volume":"25","author":"Lee S","year":"2023","unstructured":"Lee S, Toft NJ, Axelsen TV, Espejo MS, Pedersen TM, Mele M, Pedersen HL, Balling E, Johansen T, Burton M, et al. Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2\/HER2-enriched breast cancer. Breast Cancer Res. 2023;25(1):46.","journal-title":"Breast Cancer Res"},{"key":"e_1_3_4_88_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cbpa.2015.02.005","article-title":"Targeting carbonic anhydrase IX with small organic ligands","volume":"26","author":"Wichert M","year":"2015","unstructured":"Wichert M, Krall N. Targeting carbonic anhydrase IX with small organic ligands. Curr Opin Chem Biol. 2015;26:48\u201354.","journal-title":"Curr Opin Chem Biol"},{"issue":"7","key":"e_1_3_4_89_1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors","volume":"43","author":"McDonald PC","year":"2020","unstructured":"McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L, Singh M, Zhang Z, Supuran CT, Renouf DJ, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol. 2020;43(7):484\u2013490.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"e_1_3_4_90_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/14756366.2018.1532419","article-title":"The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy","volume":"34","author":"Andreucci E","year":"2019","unstructured":"Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, Supuran CT, Calorini L. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem. 2019;34(1):117\u2013123.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"e_1_3_4_91_1","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-025-00690-z","article-title":"An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo","volume":"14","author":"Gazzaroli G","year":"2025","unstructured":"Gazzaroli G, Tavani C, Filiberti S, et al. An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo. Exp Hematol Oncol. 2025;14(1):104.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"e_1_3_4_92_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/0008-5472.CAN-08-2470","article-title":"Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH","volume":"69","author":"Chiche J","year":"2009","unstructured":"Chiche J, Ilc K, Laferri\u00e8re J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyss\u00e9gur J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009;69(1):358\u2013368.","journal-title":"Cancer Res"},{"issue":"3","key":"e_1_3_4_93_1","first-page":"1713","volume":"364","author":"Mboge MY","year":"2021","unstructured":"Mboge MY, Coombs J, Singh S, et al. Inhibition of carbonic anhydrase using slc-149: support for a noncatalytic function of CAIX in breast cancer. J Med Chem. 2021;364(3):1713\u20131724.","journal-title":"Inhibition of carbonic anhydrase using slc-149: support for a noncatalytic function of CAIX in breast cancer"},{"issue":"16","key":"e_1_3_4_94_1","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.3390\/ijms22168808","article-title":"Betulin sulfonamides as carbonic anhydrase inhibitors and anticancer agents in breast cancer cells","volume":"22","author":"G\u00fcttler A","year":"2021","unstructured":"G\u00fcttler A, Eiselt Y, Funtan A, Thiel A, Petrenko M, Ke\u00dfler J, Thondorf I, Paschke R, Vordermark D, Bache M, et al. Betulin sulfonamides as carbonic anhydrase inhibitors and anticancer agents in breast cancer cells. Int J Mol Sci. 2021;22(16):8808.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"e_1_3_4_95_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1021\/acs.jmedchem.9b01669","article-title":"\u201cA sweet combination\u201d: developing saccharin and acesulfame K structures for selectively targeting the tumor-associated carbonic anhydrases IX and XII","volume":"63","author":"Bua S","year":"2020","unstructured":"Bua S, Lomelino C, Murray AB, Osman SM, ALOthman ZA, Bozdag M, Abdel-Aziz HA, Eldehna WM, McKenna R, Nocentini A, et al. \u201cA sweet combination\u201d: developing saccharin and acesulfame K structures for selectively targeting the tumor-associated carbonic anhydrases IX and XII. J Med Chem. 2020;63(1):321\u2013333.","journal-title":"J Med Chem"},{"issue":"17","key":"e_1_3_4_96_1","doi-asserted-by":"crossref","first-page":"18389","DOI":"10.1021\/acs.jmedchem.5c01142","article-title":"Di-meta-substituted fluorinated benzenesulfonamides as potent and selective anticancer inhibitors of carbonic anhydrase IX and XII","volume":"68","author":"Va\u0161kevi\u010dius A","year":"2025","unstructured":"Va\u0161kevi\u010dius A, \u017dvirblis M, Kurtenoka M, Leitans J, Manakova E, Paketuryt\u0117-Latv\u0117 V, Kvietkauskait\u0117 A, Kazaks A, Eimonta V, \u010cerepenkait\u0117 K, et al. Di-meta-substituted fluorinated benzenesulfonamides as potent and selective anticancer inhibitors of carbonic anhydrase IX and XII. J Med Chem. 2025;68(17):18389\u201318406.","journal-title":"J Med Chem"},{"issue":"8","key":"e_1_3_4_97_1","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1021\/ja809683v","article-title":"Non-zinc mediated inhibition of carbonic anhydrases:coumarins are a new class of suicide inhibitors","volume":"131","author":"Maresca A","year":"2009","unstructured":"Maresca A, Temperini C, Vu H, Pham NB, Poulsen S-A, Scozzafava A, Quinn RJ, Supuran CT. Non-zinc mediated inhibition of carbonic anhydrases:coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009;131(8):3057\u20133062.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"e_1_3_4_98_1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1535-7163.MCT-13-0653","article-title":"Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux","volume":"13","author":"Draoui N","year":"2014","unstructured":"Draoui N, Schicke O, Seront E, Bouzin C, Sonveaux P, Riant O, Feron O. Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. Mol Cancer Ther. 2014;13(6):1410\u20131418.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"e_1_3_4_99_1","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12035-021-02437-3","article-title":"The carbonic anhydrase inhibitor E7070 sensitizes glioblastoma cells to radio-and chemotherapy and reduces tumor growth","volume":"58","author":"Teixeira SA","year":"2021","unstructured":"Teixeira SA, Viapiano MS, Andrade AF, Nandhu MS, Pezuk JA, Bidinotto LT, Suazo VK, Neder L, Carlotti CG, Becker AP, et al. The carbonic anhydrase inhibitor E7070 sensitizes glioblastoma cells to radio-and chemotherapy and reduces tumor growth. Mol Neurobiol. 2021;58(9):4520\u20134534.","journal-title":"Mol Neurobiol"},{"key":"e_1_3_4_100_1","doi-asserted-by":"crossref","first-page":"108224","DOI":"10.1016\/j.bioorg.2025.108224","article-title":"Carbonic anhydrase inhibitors: structural insights and therapeutic potential","volume":"156","author":"Singh P","year":"2025","unstructured":"Singh P, Arifuddin M, Supuran CT, Nerella SG. Carbonic anhydrase inhibitors: structural insights and therapeutic potential. Bioorg Chem. 2025;156:108224.","journal-title":"Bioorg Chem"},{"issue":"9","key":"e_1_3_4_101_1","doi-asserted-by":"crossref","first-page":"e0328305","DOI":"10.1371\/journal.pone.0328305","article-title":"A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy","volume":"20","author":"Eissa IH","year":"2025","unstructured":"Eissa IH, Elkady H, Elgammal WE, Mahdy HA, Husein DZ, Amin FG, Elsheshiny AAA, Abdelfattah SS, Alsfouk AA, Elkaeed EB, et al. A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy. PLoS One. 2025;20(9):e0328305.","journal-title":"PLoS One"},{"issue":"5","key":"e_1_3_4_102_1","doi-asserted-by":"crossref","first-page":"108482","DOI":"10.1016\/j.jbc.2025.108482","article-title":"Bifunctional compounds for targeted degradation of carbonic anhydrase IX through integrin-facilitated lysosome degradation","volume":"301","author":"He W","year":"2025","unstructured":"He W, Chen C, Cai R, Zheng J, Yao M, Shim JS, Kwok HF, Yao X, Fang L, Chen L, et al. Bifunctional compounds for targeted degradation of carbonic anhydrase IX through integrin-facilitated lysosome degradation. J Biol Chem. 2025;301(5):108482.","journal-title":"J Biol Chem"},{"key":"e_1_3_4_103_1","doi-asserted-by":"crossref","first-page":"855019","DOI":"10.3389\/fonc.2022.855019","article-title":"pH-responsive polymer nanomaterials for tumor therapy","volume":"12","author":"Chu S","year":"2022","unstructured":"Chu S, Shi X, Tian Y, Gao F. pH-responsive polymer nanomaterials for tumor therapy. Front Oncol. 2022;12:855019.","journal-title":"Front Oncol"},{"issue":"6","key":"e_1_3_4_104_1","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/med.21720","article-title":"Making smart drugs smarter: the importance of linker chemistry in targeted drug delivery","volume":"40","author":"Yang X","year":"2020","unstructured":"Yang X, Pan Z, Choudhury MR, Yuan Z, Anifowose A, Yu B, Wang W, Wang B. Making smart drugs smarter: the importance of linker chemistry in targeted drug delivery. Med Res Rev. 2020;40(6):2682\u20132713.","journal-title":"Med Res Rev"},{"issue":"9","key":"e_1_3_4_105_1","doi-asserted-by":"crossref","first-page":"11681","DOI":"10.3390\/ijms130911681","article-title":"Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(\u03b2-l-malic acid)","volume":"13","author":"Patil R","year":"2012","unstructured":"Patil R, Portilla-Arias J, Ding H, Konda B, Rekechenetskiy A, Inoue S, Black KL, Holler E, Ljubimova JY. Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(\u03b2-l-malic acid). Int J Mol Sci. 2012;13(9):11681\u201311693.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_106_1","doi-asserted-by":"crossref","first-page":"118172","DOI":"10.1016\/j.bmc.2025.118172","article-title":"Unlocking pH-responsive dual payload release through hydrazone linkage chemistry","volume":"123","author":"Abd-Ellah HS","year":"2025","unstructured":"Abd-Ellah HS, Zhao D, Zhou Y, Baell JB. Unlocking pH-responsive dual payload release through hydrazone linkage chemistry. Bioorg Med Chem. 2025;123:118172.","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"e_1_3_4_107_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/molecules31050851","article-title":"A pH\/enzyme-sensitive doxorubicin prodrug micelle for safe and effective cancer treatment","volume":"31","author":"Li X","year":"2026","unstructured":"Li X, Wang D, Wu S, Na N, Yang X, Yi D, Zhang Z, Liang Q, Zhao Z, Hua Y, et al. A pH\/enzyme-sensitive doxorubicin prodrug micelle for safe and effective cancer treatment. Molecules. 2026;31(5):851.","journal-title":"Molecules"},{"issue":"1","key":"e_1_3_4_108_1","first-page":"29","article-title":"CaCO3-assisted preparation of pH-responsive immune-modulating nanoparticles for augmented chemo-immunotherapy","volume":"13","author":"Zhu Y","year":"2020","unstructured":"Zhu Y, Yang Z, Dong Z, Gong Y, Hao Y, Tian L, Yang X, Liu Z, Feng L. CaCO3-assisted preparation of pH-responsive immune-modulating nanoparticles for augmented chemo-immunotherapy. Nanomicro Lett. 2020;13(1):29.","journal-title":"Nanomicro Lett"},{"key":"e_1_3_4_109_1","doi-asserted-by":"crossref","first-page":"1082290","DOI":"10.3389\/fbioe.2022.1082290","article-title":"Tumor treatment by pHLIP-targeted antigen delivery","volume":"10","author":"DuPont M","year":"2022","unstructured":"DuPont M, Visca H, Moshnikova A, Engelman DM, Reshetnyak YK, Andreev OA. Tumor treatment by pHLIP-targeted antigen delivery. Front Bioeng Biotechnol. 2022;10:1082290.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"e_1_3_4_110_1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s11307-022-01737-x","article-title":"pHLIP peptides target acidity in activated macrophages","volume":"24","author":"Visca H","year":"2022","unstructured":"Visca H, DuPont M, Moshnikova A, Crawford T, Engelman DM, Andreev OA, Reshetnyak YK. pHLIP peptides target acidity in activated macrophages. Mol Imaging Biol. 2022;24(6):874\u2013885.","journal-title":"Mol Imaging Biol"},{"issue":"36","key":"e_1_3_4_111_1","doi-asserted-by":"crossref","first-page":"30543","DOI":"10.1021\/acsami.7b10840","article-title":"Tumor Acidic microenvironment targeted drug delivery based on pHLIP-modified mesoporous organosilica nanoparticles","volume":"9","author":"Zhang Y","year":"2017","unstructured":"Zhang Y, Dang M, Tian Y, Zhu Y, Liu W, Tian W, Su Y, Ni Q, Xu C, Lu N, et al. Tumor Acidic microenvironment targeted drug delivery based on pHLIP-modified mesoporous organosilica nanoparticles. ACS Appl Mater Interfaces. 2017;9(36):30543\u201330552.","journal-title":"ACS Appl Mater Interfaces"},{"key":"e_1_3_4_112_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.01.007","article-title":"Targeting monocarboxylate transporters (MCTs) in cancer: how close are we to the clinics?","volume":"90","author":"Singh M","year":"2023","unstructured":"Singh M, Afonso J, Sharma D, Gupta R, Kumar V, Rani R, Baltazar F, Kumar V. Targeting monocarboxylate transporters (MCTs) in cancer: how close are we to the clinics? Semin Cancer Biol. 2023;90:1\u201314.","journal-title":"Semin Cancer Biol"},{"key":"e_1_3_4_113_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/JEP.S265620","article-title":"Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors","volume":"12","author":"Supuran CT.","year":"2020","unstructured":"Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol. 2020;12:603\u2013617.","journal-title":"J Exp Pharmacol"},{"issue":"14","key":"e_1_3_4_114_1","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3390\/cancers14143297","article-title":"Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside","volume":"14","author":"McDonald PC","year":"2022","unstructured":"McDonald PC, Chafe SC, Supuran CT, Dedhar S. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside. Cancers (Basel). 2022;14(14):3297.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"e_1_3_4_115_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.37349\/etat.2020.00005","article-title":"The impact of tumour pH on cancer progression: strategies for clinical intervention","volume":"1","author":"Ward C","year":"2020","unstructured":"Ward C, Meehan J, Gray ME, Murray AF, Argyle DJ, Kunkler IH, Langdon SP. The impact of tumour pH on cancer progression: strategies for clinical intervention. Explor Targeted Antitumor Therapy. 2020;1(2):71\u2013100.","journal-title":"Explor Targeted Antitumor Therapy"},{"issue":"4","key":"e_1_3_4_116_1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/cas.15722","article-title":"Metabolic adaptations of cancer in extreme tumor microenvironments","volume":"114","author":"Nakahara R","year":"2023","unstructured":"Nakahara R, Maeda K, Aki S, Osawa T. Metabolic adaptations of cancer in extreme tumor microenvironments. Cancer Sci. 2023;114(4):1200\u20131207.","journal-title":"Cancer Sci"},{"issue":"1","key":"e_1_3_4_117_1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/14756366.2022.2052868","article-title":"Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies","volume":"37","author":"Kciuk M","year":"2022","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Mojzych M, Marciniak B, Drozda R, Kontek R. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J Enzyme Inhib Med Chem. 2022;37(1):1278\u20131298.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"2","key":"e_1_3_4_118_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s12276-026-01650-1","article-title":"Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver","volume":"58","author":"Kim TH","year":"2026","unstructured":"Kim TH, Lim SH, Lee H, Chae YC, Min DS. Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver. Exp Mol Med. 2026;58(2):366\u2013381.","journal-title":"Exp Mol Med"},{"issue":"15","key":"e_1_3_4_119_1","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.yexcr.2010.06.005","article-title":"NBCn1 and NHE1 expression and activity in \u0394NErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance","volume":"316","author":"Lauritzen G","year":"2010","unstructured":"Lauritzen G, Jensen MBF, Boedtkjer E, Dybboe R, Aalkjaer C, Nylandsted J, Pedersen SF. NBCn1 and NHE1 expression and activity in \u0394NErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance. Exp Cell Res. 2010;316(15):2538\u20132553.","journal-title":"Exp Cell Res"},{"issue":"12","key":"e_1_3_4_120_1","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/s41418-025-01532-5","article-title":"Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes","volume":"32","author":"Dreute J","year":"2025","unstructured":"Dreute J, Stengel J, Becher J, van den Borre D, Pfisterer M, Bartkuhn M, Beutgen VM, Ndreshkjana B, G\u00e4rtner U, Graumann J, et al. Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes. Cell Death Differ. 2025;32(12):2239\u20132256.","journal-title":"Cell Death Differ"},{"issue":"8","key":"e_1_3_4_121_1","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.7150\/ijbs.129129","article-title":"SLC4A7 drives NSCLC progression and immune evasion via pH dysregulation: its targeting synergizes with anti-PD-1\/L1 therapy","volume":"22","author":"Qin H","year":"2026","unstructured":"Qin H, Tang D, Li Z, Yang F, Wang J, Liu X, Chen C, Gao W. SLC4A7 drives NSCLC progression and immune evasion via pH dysregulation: its targeting synergizes with anti-PD-1\/L1 therapy. Int J Biol Sci. 2026;22(8):3950\u20133968.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"e_1_3_4_122_1","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1021\/acs.jmedchem.4c00239","article-title":"Discovery and mechanistic studies of dual-target hits for carbonic anhydrase IX and VEGFR-2 as potential agents for solid tumors: X-ray, in vitro, in vivo, and in silico investigations of coumarin-based thiazoles","volume":"67","author":"Hefny SM","year":"2024","unstructured":"Hefny SM, El-Moselhy TF, El-Din N, Giovannuzzi S, Bin Traiki T, Vaali-Mohammed M-A, El-Dessouki AM, Yamaguchi K, Sugiura M, Shaldam MA, et al. Discovery and mechanistic studies of dual-target hits for carbonic anhydrase IX and VEGFR-2 as potential agents for solid tumors: X-ray, in vitro, in vivo, and in silico investigations of coumarin-based thiazoles. J Med Chem. 2024;67(9):7406\u20137430.","journal-title":"J Med Chem"},{"issue":"15","key":"e_1_3_4_123_1","doi-asserted-by":"crossref","first-page":"10217","DOI":"10.1021\/jacs.3c14005","article-title":"Nanomedicine remodels tumor microenvironment for solid tumor immunotherapy","volume":"146","author":"Guo Y","year":"2024","unstructured":"Guo Y, Hu P, Shi J. Nanomedicine remodels tumor microenvironment for solid tumor immunotherapy. J Am Chem Soc. 2024;146(15):10217\u201310233.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"e_1_3_4_124_1","doi-asserted-by":"crossref","first-page":"e5768926","DOI":"10.1155\/jimr\/5768926","article-title":"A hidden checkpoint: bidirectional pH remodeling of the immunological synapse in cancer, methods, and therapeutic opportunities","volume":"2026","author":"Guillemette A","year":"2026","unstructured":"Guillemette A, Gez E, Titah S, Touil Y. A hidden checkpoint: bidirectional pH remodeling of the immunological synapse in cancer, methods, and therapeutic opportunities. J Immunol Res. 2026;2026(1):e5768926.","journal-title":"J Immunol Res"},{"issue":"3","key":"e_1_3_4_125_1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1039\/D2CS00479H","article-title":"Engineering lactate-modulating nanomedicines for cancer therapy","volume":"52","author":"Chen J","year":"2023","unstructured":"Chen J, Zhu Y, Wu C, Shi J. Engineering lactate-modulating nanomedicines for cancer therapy. Chem Soc Rev. 2023;52(3):973\u20131000.","journal-title":"Chem Soc Rev"},{"key":"e_1_3_4_126_1","doi-asserted-by":"crossref","first-page":"105248","DOI":"10.1016\/j.jddst.2023.105248","article-title":"Targeting the oral tumor microenvironment by nanoparticles: a review of progresses","volume":"91","author":"Zhang H","year":"2024","unstructured":"Zhang H, Zhou F, Yang Q, Huang M. Targeting the oral tumor microenvironment by nanoparticles: a review of progresses. J Drug Deliv Sci Technol. 2024;91:105248.","journal-title":"J Drug Deliv Sci Technol"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2706109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2706109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2706109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:56:48Z","timestamp":1785862608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2706109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2706109"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2706109","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2706109"}}